Effects of once-daily extended release quetiapine fumarate on patient-reported outcomes in patients with generalized anxiety disorder

References

• WittchenHUGeneralized anxiety disorder: prevalence, burden, and cost to societyDepress Anxiety200216416217112497648
   PubMed Web of Science ®Google Scholar
• CarterRMWittchenHUPfisterHKesslerRCOne-year prevalence of subthreshold and threshold DSM-IV generalized anxiety disorder in a nationally representative sampleDepress Anxiety2001132788811301924
   PubMed Web of Science ®Google Scholar
• JacobiFWittchenHUHoltingCPrevalence, co-morbidity and correlates of mental disorders in the general population: results from the German Health Interview and Examination Survey (GHS)Psychol Med200434459761115099415
   PubMed Web of Science ®Google Scholar
• WittchenHUZhaoSKesslerRCEatonWWDSM-III-R generalized anxiety disorder in the National Comorbidity SurveyArch Gen Psychiatry19945153553648179459
   PubMed Web of Science ®Google Scholar
• WittchenHUCarterRMPfisterHMontgomerySAKesslerRCDisabilities and quality of life in pure and comorbid generalized anxiety disorder and major depression in a national surveyInt Clin Psychopharmacol200015631932811110007
   PubMed Web of Science ®Google Scholar
• MassionAOWarshawMGKellerMBQuality of life and psychiatric morbidity in panic disorder and generalized anxiety disorderAm J Psychiatry199315046006078465877
   PubMed Web of Science ®Google Scholar
• YonkersKADyckIRWarshawMKellerMBFactors predicting the clinical course of generalised anxiety disorderBr J Psychiatry200017654454910974960
   PubMed Web of Science ®Google Scholar
• BallengerJCDavidsonJRTLecrubierYConsensus statement on generalized anxiety disorder from the International Consensus Group on Depression and AnxietyJ Clin Psychiatry200162Suppl 11535811414552
   PubMed Web of Science ®Google Scholar
• RogersMPWarshawMGGoismanRMComparing primary and secondary generalized anxiety disorder in a long-term naturalistic study of anxiety disordersDepress Anxiety19991011710499183
   PubMed Web of Science ®Google Scholar
• BandelowBZoharJHollanderEKasperSMollerHJWorld Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the pharmacological treatment of anxiety, obsessive-compulsive and post-traumatic stress disorders – First revisionWorld J Biol Psychiatry20089424831218949648
   PubMed Web of Science ®Google Scholar
• PollackMHEndicottJLiebowitzMExamining quality of life in patients with generalized anxiety disorder: clinical relevance and response to duloxetine treatmentJ Psychiatr Res200842121042104918221755
   PubMed Web of Science ®Google Scholar
• DemyttenaereKAndersenHFReinesEHImpact of escitalopram treatment on Quality of Life Enjoyment and Satisfaction Questionnaire scores in major depressive disorder and generalized anxiety disorderInt Clin Psychopharmacol200823527628618703937
   PubMed Web of Science ®Google Scholar
• MontiJMMontiDSleep disturbance in generalized anxiety disorder and its treatmentSleep Med Rev20004326327612531169
   PubMed Web of Science ®Google Scholar
• MullenJJibsonMDSweitzerDA comparison of the relative safety, efficacy, and tolerability of quetiapine and risperidone in outpatients with schizophrenia and other psychotic disorders: the quetiapine experience with safety and tolerability (QUEST) studyClin Ther200123111839185411768836
   PubMed Web of Science ®Google Scholar
• CalabreseJRKeckPEJrMacFaddenWA randomized, double-blind, placebo-controlled trial of quetiapine in the treatment of bipolar I or II depressionAm J Psychiatry200516271351136015994719
   PubMed Web of Science ®Google Scholar
• ThaseMEMacFaddenWWeislerRHEfficacy of quetiapine monotherapy in bipolar I and II depression: a double-blind, placebocontrolled study (the BOLDER II study)J Clin Psychopharmacol200626660060917110817
   PubMed Web of Science ®Google Scholar
• KatzmanMAVermaniMJacobsLQuetiapine as an adjunctive pharmacotherapy for the treatment of non-remitting generalized anxiety disorder: a flexible-dose, open-label pilot trialJ Anxiety Disord20082281480148618455360
   PubMed Web of Science ®Google Scholar
• EndicottJPaulssonBGustafssonUSchiolerHHassanMQuetiapine monotherapy in the treatment of depressive episodes of bipolar I and II disorder: improvements in quality of life and quality of sleepJ Affect Disord20081112–330631918774180
   PubMed Web of Science ®Google Scholar
• DattoCBerggrenLPatelJBErikssonHSelf-reported sedation profile of immediate-release quetiapine fumarate compared with extended-release quetiapine fumarate during dose initiation: a randomized, double-blind, crossover study in healthy adult subjectsClin Ther200931349250219393840
   PubMed Web of Science ®Google Scholar
• KahnRSSchulzSCPalazovVDEfficacy and tolerability of once-daily extended release quetiapine fumarate in acute schizophrenia: a randomized, double-blind, placebo-controlled studyJ Clin Psychiatry200768683284217592906
   PubMed Web of Science ®Google Scholar
• KhanAJoyceMAtkinsonSEggensIBaldytchevaIErikssonHA randomized, double-blind study of once-daily extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalized anxiety disorderJ Clin Psychopharmacol201131441842821694613
   PubMed Web of Science ®Google Scholar
• MeridethCCutlerAJSheFErikssonHEfficacy and tolerability of extended release quetiapine fumarate monotherapy in the acute treatment of generalized anxiety disorder: a randomized, placebo controlled and active-controlled studyInt Clin Psychopharmacol2012271405422045039
   PubMed Web of Science ®Google Scholar
• BandelowBChouinardGBobesJExtended-release quetiapine fumarate (quetiapine XR): a once-daily monotherapy effective in generalized anxiety disorder. Data from a randomized, double-blind, placebo- and active-controlled studyInt J Neuropsychopharmacol201013330532019691907
   PubMed Web of Science ®Google Scholar
• MagiKMezhebovskyISheFDattoCErikssonHAEfficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in elderly patients with generalised anxiety disorder (GAD)World J Biol Psychiatry200910239
   Google Scholar
• KatzmanMABrawman-MintzerOReyesEBOlaussonBLiuSErikssonHExtended release quetiapine fumarate (quetiapine XR) monotherapy as maintenance treatment for generalized anxiety disorder: a long-term, randomized, placebo-controlled trialInt Clin Psychopharmacol2011261112420881846
   PubMed Web of Science ®Google Scholar
• SteinDJBandelowBMeridethCOlaussonBSzamosiJErikssonHEfficacy and tolerability of extended release quetiapine fumarate (quetiapine XR) monotherapy in patients with generalised anxiety disorder: an analysis of pooled data from three 8-week placebo- controlled studiesHum Psychopharmacol201126861462822143997
   PubMed Web of Science ®Google Scholar
• American Psychiatric AssociationDiagnostic and Statistical Manual of Mental DisordersFourth Edition Text RevisionWashington, DCAmerican Psychiatric Association2000
   Google Scholar
• SheehanDVLecrubierYSheehanKHThe Mini-International Neuropsychiatric Interview (MINI): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10J Clin Psychiatry199859Suppl 2022339881538
   PubMed Web of Science ®Google Scholar
• EndicottJNeeJHarrisonWBlumenthalRQuality of Life Enjoyment and Satisfaction Questionnaire: a new measurePsychopharmacol Bull19932923213268290681
   PubMed Web of Science ®Google Scholar
• BuysseDJReynoldsCFIIIMonkTHBermanSRKupferDJThe Pittsburgh Sleep Quality Index: a new instrument for psychiatric practice and researchPsychiatry Res19892821932132748771
   PubMed Web of Science ®Google Scholar
• SheehanDVThe Anxiety DiseaseNew York, NYScribner1996
   Google Scholar
• WyrwichKHarnamNRevickiDALocklearJCSvedsaterHEndicottJAssessing health-related quality of life in generalized anxiety disorder using the Quality Of Life Enjoyment and Satisfaction QuestionnaireInt Clin Psychopharmacol200924628929519707153
   PubMed Web of Science ®Google Scholar
• EndicottJRussellJMRaskinJDuloxetine treatment for role functioning improvement in generalized anxiety disorder: three independent studiesJ Clin Psychiatry200768451852417474806
   PubMed Web of Science ®Google Scholar
• den BoerJAEvansDLLeeSSalin-PascualRUnraveling the diagnostic clues of depression and GAD: the primary care challengePsychopharmacol Bull200236Suppl 215015712490831
   PubMedGoogle Scholar
• NuttDArgyropoulosSHoodSPotokarJGeneralized anxiety disorder: a comorbid diseaseEur Neuropsychopharmacol200616Suppl 2S10911816737802
   PubMed Web of Science ®Google Scholar
• BelangerLMorinCMLangloisFLadouceurRInsomnia and generalized anxiety disorder: effects of cognitive behavior therapy for gad on insomnia symptomsJ Anxiety Disord200418456157115149714
   PubMed Web of Science ®Google Scholar
• RosenthalMTiagabine for the treatment of generalized anxiety disorder: a randomized, open-label, clinical trial with paroxetine as a positive controlJ Clin Psychiatry200364101245124914658975
   PubMed Web of Science ®Google Scholar
• FontaineRBeaudryPLe MorvanPBeauclairLChouinardGZopiclone and triazolam in insomnia associated with generalized anxiety disorder: a placebo-controlled evaluation of efficacy and daytime anxietyInt Clin Psychopharmacol1990531731832230061
   PubMed Web of Science ®Google Scholar
• KennedyBLLinYSchwabJJWork, social, and family disabilities of subjects with anxiety and depressionSouth Med J200295121424142712597311
   PubMed Web of Science ®Google Scholar
• PollackMHZaninelliRGoddardAParoxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trialJ Clin Psychiatry200162535035711411817
   PubMed Web of Science ®Google Scholar
• RynnMRussellJEricksonJEfficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trialDepress Anxiety200825318218917311303
   PubMed Web of Science ®Google Scholar
• KesslerRCKellerMBWittchenHUThe epidemiology of generalized anxiety disorderPsychiatr Clin North Am2001241193911225507
   PubMed Web of Science ®Google Scholar
• WeillerEBisserbeJCMaierWLecrubierYPrevalence and recognition of anxiety syndromes in five European primary care settings. A report from the WHO study on Psychological Problems in General Health CareBr J Psychiatry1998173Suppl 341823
   Web of Science ®Google Scholar
• AstraZenecaSeroquel XR – Summary of product characteristics for Ireland Available from: http://www.medicines.ie/medicine/13032/SPC/Seroquel+XR+50mg%2c+150mg%2c+200mg%2c+300mg%2c+400mg+prolonged-release+tablets/Accessed May 24, 2012
   Google Scholar
• AstraZenecaSeroquel XR (quetiapine fumarate) extended-release tablets/US prescribing information Available from: http://www1.astrazeneca-us.com/pi/seroquelxr.pdfAccessed May 24, 2012
   Google Scholar
• CutlerAJMontgomerySAFeifelDLazarusAÅströmMBrecherMExtended release quetiapine fumarate monotherapy in major depressive disorder: a placebo- and duloxetine-controlled studyJ Clin Psychiatry200970452653919358790
   PubMed Web of Science ®Google Scholar
• WeislerRJoyceMMcGillLLazarusASzamosiJErikssonHExtended release quetiapine fumarate monotherapy for major depressive disorder: results of a double-blind, randomized, placebo-controlled studyCNS Spectr200914629931319668121
   PubMed Web of Science ®Google Scholar
• LiebowitzMLamRWLepolaUDattoCSweitzerDErikssonHEfficacy and tolerability of extended release quetiapine fumarate monotherapy as maintenance treatment of major depressive disorder: a randomized, placebo-controlled trialDepress Anxiety2010271096497620734365
   PubMed Web of Science ®Google Scholar